Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma



Status:Not yet recruiting
Conditions:Blood Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:7/27/2016
End Date:July 2021
Contact:Bayer Clinical Trials Contact
Email:clinical-trials-contact@bayerhealthcare.com

Use our guide to learn which trials are right for you!

A Phase 1b/2 Trial to Evaluate the Safety and Efficacy of Radium-223 Dichloride (BAY88-8223) in Combination With Bortezomib and Dexamethasone in Early Relapsed Multiple Myeloma

This study will be conducted in 2 parts. The phase 1b part will be an international, phase
1b, open-label, dose-escalation assessment of radium-223 dichloride administered with
bortezomib and dexamethasone in subjects with relapsed multiple myeloma. The primary
endpoint of the phase 1b part is to determine the optimal dose of radium-223 dichloride in
combination with bortezomib/dexamethasone for the Phase 2 portion of the study.

The phase 2 part will be an international, phase 2, double-blind, randomized,
placebo-controlled assessment of radium-223 dichloride versus placebo administered with
bortezomib and dexamethasone, in subjects with relapsed multiple myeloma. Randomization
(1:1) in the phase 2 part will be stratified by:

- Prior bortezomib treatment (yes, no)

- Prior treatment (1 prior line of treatment, >1 prior line of treatment) Approximately
30 subjects (10 subjects per cohort) will be enrolled in the phase 1b part of the study
and approximately 196 subjects will be enrolled in the phase 2 part of the study.


Inclusion Criteria:

- Cytologically or histologically confirmed diagnosis of multiple myeloma

- Subjects must have received at least 1 and not more than 3 previous lines of
treatment and have had a response to treatment (i.e., achieved a minimal response
[MR] or better) according to the International Myeloma Working Group (IMWG) uniform
response criteria

- Subjects must have had progressive disease according to the IMWG uniform response
criteria following the last multiple myeloma treatment

- Subjects must have measurable disease defined as at least 1 of the following
(according to central laboratory results):

- Serum M-protein ≥1 g/dL

- Urine M-protein ≥200 mg/24 hours

- Serum free light chain (FLC) ≥10 mg/dL with abnormal ratio

- ≥1 bone lesion identifiable by radiograph, computed tomography, magnetic resonance
imaging, or bone scintigraphy

- Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2

- Subjects must be nonrefractory to bortezomib and had no progression during or within
60 days after completion of bortezomib

- Absolute neutrophil count (ANC) ≥1.5 × 10e9/L, hemoglobin (Hb) ≥9.0 g/dL, and
platelet count ≥75.0 × 10e9/L independent of transfusion of red blood cells (RBC) or
platelet concentrates and independent of granulocyte colony stimulating factor
(G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF)

Exclusion Criteria:

- Systemic glucocorticoid therapy (prednisone >10 mg/day orally or equivalent) within
the last 4 weeks prior to first dose, unless tapered and on a stable dose ≤10 mg/day
for at least 1 week

- Subjects with known POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy,
monoclonal protein, and skin changes) or light chain (AL) amyloidosis

- Plasma cell leukemia

- Systemic anti-cancer therapy within 4 weeks prior to first dose

- Radiation therapy in the previous 4 weeks prior to first dose except if given for
pain management and involves less than 10% of the bone marrow

- Prior treatment with radium-223 dichloride or any experimental radiopharmaceutical

- Congestive heart failure (New York Heart Association [NYHA] class III to IV),
symptomatic cardiac ischemia, cardiomyopathy, clinically relevant ventricular
arrhythmia, pericardial disease, unstable angina or myocardial infarct in the
previous 6 months prior to first dose, left ventricular ejection fraction <40%

- Neuropathy ≥ Grade 2 or Grade 1 with pain
We found this trial at
11
sites
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Adelaide,
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Encinitas, CA
Click here to add this to my saved trials
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
?
mi
from
Metairie, LA
Click here to add this to my saved trials
?
mi
from
Rockville, MD
Click here to add this to my saved trials
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Watertown, SD
Click here to add this to my saved trials
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials